Skip to main content
. Author manuscript; available in PMC: 2023 Jun 1.
Published in final edited form as: Cancer Chemother Pharmacol. 2022 May 4;89(6):795–807. doi: 10.1007/s00280-022-04436-0

Figure 1.

Figure 1.

PK and NCA of BAY-1895344 from bioavailability and dose linearity studies. A) Mean plasma concentration versus time profiles for 4IV (•), 1PO (○), 4PO (◇), 10PO (△), 40PO (□). B) Mean plasma concentrations normalized by administered dose versus time profiles C) Dose-normalized Cmax (ANOVA test of PO treated groups, p=0.0005) D) Dose-normalized AUC0-∞ (ANOVA test of PO treated groups, p<0.0001). Error bars represent ± SD for concentrations and ± SEM for AUC.